Sales of a high-tech wrap derived from sheep guts that assists in human healing is behind solid traction and profits in the United States for an ASX-listed Kiwi company.
Aroa Biosurgery made $NZ103.9 million ($84.9 million) in revenue in the year ended March 31, up 23 per cent from 2024/25, the company announced on Tuesday.
Its gross profit rose 23 per cent to $NZ88.8 million ($72.5 million) and Aroa posted normalised earnings of $NZ11 million ($9 million), beating guidance of $5 million to $8 million, in what the company called a "breakout year".
Sales of Aroa's Myriad collagen matrix, which is made from sheep forestomach tissue, were up 54 per cent to $NZ49.5 million ($40.4 million).
Aroa chief executive and founder Brian Ward told analysts the company makes a 90 per cent profit margin on Myriad sales and its healing properties are backed by strong clinical evidence.
